Yingjie Huang

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

Michael A. Davies, Philippe Saïag, Caroline Robert et al. · The Lancet Oncology · 2017 · 759 citations · Full text

Medicine, Melanoma, Pathology +5

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial

J. Randolph Hecht, Yung‐Jue Bang, Shukui Qin et al. · Journal of Clinical Oncology · 2015 · 611 citations · Full text

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer

Michael P. Chu, J. Randolph Hecht, Dennis J. Slamon et al. · JAMA Oncology · 2016 · 105 citations · Full text

Incidence of Gastrointestinal Stromal Tumor: A Retrospective Study Based on Immunohistochemical and Mutational Analyses

Chi‐Yuan Tzen, Jiahua Wang, Yingjie Huang et al. · Digestive Diseases and Sciences · 2007 · 51 citations · Full text

Retrospective Study, Surgical Oncology, Gastrointestinal Oncology +11

Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for <i>BRAF</i>-mutant advanced melanoma: Phase 1 KEYNOTE-022 study.

Antoni Ribas, F. Stephen Hodi, Donald P. Lawrence et al. · Journal of Clinical Oncology · 2016 · 49 citations

Braf Inhibitor D, Immunology, Immunoediting +17